Please wait while the formulary information is being retrieved.
PREMPHASE (ESTROGENS, CONJUGATED/MEDROXYPROGESTERONE ACETATE)
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Vasomotor symptoms associated with menopause
- Post-menopausal osteoporosis prevention
0.625 mg(14)/0.625 mg-5mg(14) tablet
- 1 tablet by oral route once daily
Atrophic vaginitis associated with menopause
- 1 tablet by oral route once daily
Atrophy of vulva
- 1 tablet by oral route once daily
Post-menopausal osteoporosis prevention
- 1 tablet by oral route once daily
Vasomotor symptoms associated with menopause
- 1 tablet by oral route once daily
- anastrozole
- Arimidex
- Aromasin
- Cyklokapron
- exemestane
- Femara
- letrozole
- Lysteda
- tranexamic acid
Contraindicated
- None
Severe
Moderate
- A-hydrocort
- A-methapred
- Alagesic Lq
- amobarbital
- Amytal
- Anucort-hc
- Anusol-hc
- Aristospan Intra-articular
- Aristospan Intralesional
- Ascomp With Codeine
- Belladonna-phenobarbital
- betamethasone acet & sod phos
- Bivigam
- Brevital
- budesonide
- Bupap
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- Carimune Nf Nanofiltered
- Celestone Soluspan
- Cerebyx
- codeine-butalbital-ASA-caff
- Colocort
- Cortef
- Cortenema
- Cortifoam
- cortisone
- Depo-medrol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Entocort Ec
- Esgic
- ethotoin
- Evista
- Ez Use Joint-tunnel-trigger
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- First-duke's
- First-mary's Mouthwash
- Flebogamma Dif
- Flo-pred
- fludrocortisone
- fosphenytoin
- Gamastan S/d
- Gammagard Liquid
- Gammagard S-d (iga < 1 Mcg/ml)
- Gammagard S/d
- Gammaked
- Gammaplex
- Gamunex-c
- Grx Hicort 25
- Hemril-30
- Hizentra
- hydrocortisone
- hydrocortisone acetate
- hydrocortisone sod succ (PF)
- hydrocortisone sod succinate
- immune glob(IgG)(hum)-maltose
- immune globulin (human) (IgG)
- immune globulin(hum),capr(IgG)
- Kenalog
- Luminal
- Margesic
- Marten-tab
- Medrol
- Medrol (pak)
- methohexital
- methylprednisolone
- methylprednisolone acetate
- methylprednisolone sod suc(PF)
- methylprednisolone sodium succ
- methylprednisolone-bupivacaine
- Millipred
- Millipred Dp
- Mysoline
- Nembutal Sodium
- nystatin-hydrocortisone-diphen
- nystatin-TCN-HC-diphenhydramin
- Octagam
- Orapred
- Orapred Odt
- Pediapred
- Peganone
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Physicians Ez Use M-pred
- prednisolone
- prednisolone acetate
- prednisolone sodium phosphate
- prednisone
- Prednisone Intensol
- primidone
- Privigen
- Proctocort
- raloxifene
- Rayos
- Rectacort-hc
- secobarbital sodium
- Seconal Sodium
- Solu-cortef
- Solu-cortef (pf)
- Solu-medrol
- Solu-medrol (pf)
- Tencon
- triamcinolone acetonide
- triamcinolone hexacetonide
- triamcinolone-lidocaine
- Uceris
- Veripred 20
- Zebutal
- Acute myocardial infarction
- Antithrombin III deficiency
- Carcinoma of breast
- Cerebrovascular accident
- Cerebrovascular disorder
- Deep venous thrombosis
- Disease of liver
- Estrogen-dependent neoplasm
- Porphyria
- Predisposition to thrombosis
- Protein C deficiency disease
- Pulmonary thromboembolism
- Severe hepatic disease
- Thromboembolic disorder
- Thrombophilia
- Thrombophlebitis
Contraindicated
- Bed-ridden
- Coronary artery disease
- Dementia
- Endometrial carcinoma
- Family history of malignant tumor of breast
- Hereditary angioedema
- Hypercalcemia
- Increased cardiovascular event risk
- Invasive surgical procedure
- Malignant neoplasm of the ovary
- Osteopenia
- Osteoporosis
- Papilledema
- Retinal thrombosis
- Tobacco smoker
Severe
Moderate
- Asthma
- Breast fibroadenosis
- Depression
- Diabetes mellitus
- Edema
- Family history of malignant tumor of breast
- Gallbladder disease
- Hepatic porphyria
- Hyperlipidemia
- Hypertension
- Hypertriglyceridemia
- Hypoparathyroidism
- Hypothyroidism
- Migraine
- Seizure disorder
- Systemic lupus erythematosus
- Unspecified lump in breast
- Uterine leiomyoma
- Weight gain
PREMPHASE (ESTROGENS, CONJUGATED/MEDROXYPROGESTERONE ACETATE)
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Vasomotor symptoms associated with menopause
- Post-menopausal osteoporosis prevention
- Abdominal distension
- Abnormal vaginal bleeding
- Gynecomastia
- Irregular menstrual periods
- Mastalgia
- Abdominal distension
- Acute abdominal pain
- Appetite changes
- Edema
- Fatigue
- Headache disorder
- Myalgias
- Vaginitis
- Weight loss
More Frequent
Severe
Less Severe
- Back pain
- Gastroenteritis
- Weight gain
- Arthralgias
- Body fluid retention
- Candidiasis
- Constipation
- Cramps in legs
- Diarrhea
- Dizziness
- Dysmenorrhea
- Dyspepsia
- Flatulence
- General weakness
- Hypertonia
- Increased appetite
- Insomnia
- Irritability
- Migraine
- Myalgias
- Nausea
- Peripheral edema
- Symptoms of anxiety
- Vaginal discharge
- Vaginitis
- Vulvovaginal candidiasis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Abnormal vaginal bleeding
- Acute myocardial infarction
- Acute pancreatitis
- Amenorrhea
- Anaphylaxis
- Angioedema
- Asthma exacerbation
- Back pain
- Cerebrovascular accident
- Chest pain
- Cystitis
- Dementia
- Depression
- Ectopic pregnancy
- Endometrial carcinoma
- Endometrial hyperplasia
- Erythema multiforme
- Erythema nodosum
- Galactorrhea not associated with childbirth
- Gallbladder obstruction
- Hepatitis
- Hypersensitivity drug reaction
- Hypertension
- Hypotension
- Influenza
- Involuntary muscle movement
- Ischemic colitis
- Lower seizure threshold
- Malignant neoplasm of the ovary
- Menorrhagia
- Neoplasm of breast
- Nipple discharge
- Obstructive hyperbilirubinemia
- Optic neuritis
- Ovarian cyst
- Pancreatitis
- Pruritus of skin
- Pulmonary thromboembolism
- Retinal thrombosis
- Skin rash
- Thromboembolic disorder
- Thrombophlebitis
- Unspecified lump in breast
- Upper respiratory infection
- Urticaria
- Uterine leiomyoma
- Venous thrombosis
Less Severe
- Acne vulgaris
- Alopecia
- Amenorrhea
- Body fluid retention
- Cervical discharge
- Chloasma
- Constipation
- Drowsy
- Erosion of cervix
- Fever
- Hirsutism
- Hyperglycemia
- Hypertriglyceridemia
- Insomnia
- Keratoconus
- Libido changes
- Limb pain
- Mastalgia
- Migraine
- Mood changes
- Nausea
- Nervousness
- Pelvic pain
- Pruritus of skin
- Urticaria
- Vomiting
- Weight gain
- Weight loss
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Estrogens, Conjugated
May cause premature epiphyseal closure. Limited information for inducing puberty. Monitor growth in patient with bone immaturity.
Safety and efficacy not established.
- 1 Day – 18 Years
- May cause premature epiphyseal closure. Limited information for inducing puberty. Monitor growth in patient with bone immaturity.
Medroxyprogesterone (Oral)
May cause premature epiphyseal closure. Limited information for inducing puberty. Monitor growth in patient with bone immaturity.
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Conjugated Estrogens-medroxyprogesterone
- Severity Level:
2
- Additional Notes: Not indicated during pregnancy; no known dev tox with exposure during pregnancy
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Estrogens, Conjugated (oral, Inj)
May decrease quantity and quality of breastmilk.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | May decrease quantity and quality of breastmilk. |
No Known Risk
Medroxyprogesterone
Human data indicate no known adverse effect on nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | Human data indicate no known adverse effect on nursing infant |
Contraindicated
None
Precaution Exists
Estrogenic Agents (systemic)
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
Neuro/Psych-The Women's Health Initiative Memory Study demonstrated an increased relative risk (2.05, 95% CI) of probable dementia in the elderly when used in combination with estrogens.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Medroxyprogesterone Ac
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
Neuro/Psych-The Women's Health Initiative Memory Study demonstrated an increased relative risk (2.05, 95% CI) of probable dementia in the elderly when used in combination with estrogens.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Estrogens, either used alone or with a progestin, have rarely caused very serious side effects. Discuss the risks and benefits of hormone treatment with your doctor. Estrogens and progestins should not be used to prevent heart disease or dementia.<br /><br /> In postmenopausal women, estrogen when used with a progestin can increase the risk of heart disease (such as heart attacks), stroke, serious blood clots in the lungs/legs, dementia, and cancer of the breast/ovaries. The risk for serious side effects may depend on the dose of estrogen and the length of time it is used. Therefore, this medication should be used at the lowest effective dose and for the shortest amount of time.<br /><br />Discuss the use of this medication with your doctor regularly (for example, every 3 to 6 months) to see if you still need to use it. If you will be using this medication long-term, you should have regular complete physical exams (for example, once a year) as directed by your doctor. See also Notes section.
| Atrophic vaginitis associated with menopause | |
| N95.2 | Postmenopausal atrophic vaginitis |
| Atrophy of vulva | |
| N90.5 | Atrophy of vulva |
| Post-menopausal osteoporosis prevention | |
| Z78.0 | Asymptomatic menopausal state |
| Vasomotor symptoms associated with menopause | |
| N95.1 | Menopausal and female climacteric states |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
| 0-9 | A-Z |
|---|---|
| N90.5 | Atrophy of vulva |
| N95.1 | Menopausal and female climacteric states |
| N95.2 | Postmenopausal atrophic vaginitis |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
| Z78.0 | Asymptomatic menopausal state |
Formulary Reference Tool